Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasuyuki Ichimaru is active.

Publication


Featured researches published by Yasuyuki Ichimaru.


European Journal of Pharmacology | 1997

Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents

Taiichiro Imanishi; Aiko Sawa; Yasuyuki Ichimaru; Mio Miyashiro; Shinsuke Kato; Tsuneyuki Yamamoto; Showa Ueki

The effects of rolipram, a cAMP-specific phosphodiesterase (phosphodiesterase 4) inhibitor, on experimentally-induced amnesia were examined using a 3-panel runway paradigm in rats and a passive avoidance task in mice. Scopolamine, cerebral ischemia induced by four-vessel occlusion and electric convulsive shock impaired working memory in the 3-panel runway task. Rolipram at 0.1 mg/kg reduced the increase in errors induced by scopolamine or cerebral ischemia. Rolipram at 0.32 mg/kg also reduced the increase in errors induced by electric convulsive shock. Dibutyryl cAMP also had similar effects in 3-panel runway experiments. In the passive avoidance task, rolipram reversed the impairments of the avoidance response induced by scopolamine, cycloheximide and electric convulsive shock at 10, 10 and 3 mg/kg, respectively. These results indicate that rolipram ameliorates impairments of learning and memory in rats and mice, and suggest that rolipram might ameliorate the impairments of learning and memory by elevating cAMP levels.


Physiology & Behavior | 1991

Effects of anxiolytic drugs on escape behavior induced by dorsal central gray stimulation in rats

Yutaka Gomita; Minehiro Moriyama; Yasuyuki Ichimaru; Yasunori Araki

Each animal was chronically implanted with bipolar electrodes in dorsal central gray matter (DCG) and was trained to press a lever to decrease the DCG-stimulation current. Chlordiazepoxide (5-20 mg/kg, PO), diazepam (2-10 mg/kg, PO) and bromazepam (1-5 mg/kg, PO) produced dose-dependent increases in the DCG-stimulation threshold 1-4 h after administration without affecting motor performance. Meprobamate (200 mg/kg, PO) and pentobarbital (10 mg/kg, PO) also slightly increased the stimulation threshold. Their potency was in the order of bromazepam greater than diazepam greater than chlordiazepoxide greater than pentobarbital greater than meprobamate. The increase in the threshold induced by diazepam (10 mg/kg, PO) was inhibited by the GABA antagonists, bicuculline (1 mg/kg, IP) and picrotoxin (0.1 mg/kg, IP). These results suggest that decreased susceptibility to brain stimulation is involved in suppressing effects of anxiolytic drugs on the escape behavior, and also that the antiaversive action of benzodiazepines may be related to a GABAergic mechanism.


Pharmacology, Biochemistry and Behavior | 1984

Behavioral suppression using intracranial reward and punishment: effects of benzodiazepines.

Minehiro Moriyama; Yasuyuki Ichimaru; Yutaka Gomita

Rats were chronically implanted with electrodes aimed at the lateral hypothalamus (LH) and the dorsal central gray (DCG) and trained to press a lever that delivered rewarding stimulation of the LH and punishing stimulation of the DCG. In this situation, both diazepam (5-20 mg/kg, PO) and bromazepam (2-10 mg/kg, PO) caused a marked dose-dependent increase of the lever pressing response in the punished period. In addition, the facilitation of lever pressing in unpunished period was also seen in diazepam (5 and 10 mg/kg). These results show that behavioral suppression on lever pressing maintained self-stimulation reward is inducible following DCG stimulation, and that benzodiazepines exhibit an anti-behavioral suppression effect in this situation.


Japanese Journal of Pharmacology | 1995

5-HT1A-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Marble-Burying Behavior in Mice

Yasuyuki Ichimaru; Takashi Egawa; Aiko Sawa


Archive | 1991

Pyridine derivatives having angiotensin ii antagonism

Kiyoaki Katano; Hiroko Meiji Seika K.K. Yakuhin Sogo Ogino; Eiki Shitara; Hiromi Meiji Seika K.K. Yakuhin Sogo Watanabe; Jun Nagura; Naomi Osada; Yasuyuki Ichimaru; Fukio Konno; Tomoya Meiji Seika Kabushiki Kaisha Machinami; Takashi Meiji Seika Kabushiki Kaisha Tsuruoka


Japanese Journal of Pharmacology | 2000

Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice.

Tomohisa Mori; Jun Baba; Yasuyuki Ichimaru; Tsutomu Suzuki


Chemical & Pharmaceutical Bulletin | 1984

Evaluation of Isonicotinoyl-γ-Aminobutyric Acid (GABA) and Nicotinoyl-GABA as Pro-drugs of GABA

Kenji Matsuyama; Chikamasa Yamashita; Atsuko Noda; Shigeru Goto; Hiroshi Noda; Yasuyuki Ichimaru; Yutaka Gomita


Japanese Journal of Pharmacology | 1995

Neither the 5-HT1A- nor the 5-HT2-Receptor Subtype Mediates the Effect of Fluvoxamine, a Selective Serotonin Reuptake Inhibitor, on Forced-Swimming-Induced Immobility in Mice

Takashi Egawa; Yasuyuki Ichimaru; Taiichiro Imanishi; Aiko Sawa


Japanese Journal of Pharmacology | 1997

Biphasic effects of D3-receptor agonists, 7-OH-DPAT and PD128907, on the D1-receptor agonist-induced hyperactivity in mice.

Tomohisa Mori; Kenshi Murase; Jiro Tanaka; Yasuyuki Ichimaru


Archive | 1994

Antipsychotic benzoisothiazolyl piperazine derivatives

Yoshimasa Fukuda; Toshiro Sasaki; Yuuko Nakatani; Yasuyuki Ichimaru; Taiichiro Imanishi

Collaboration


Dive into the Yasuyuki Ichimaru's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eiki Shitara

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge